Bharat Biotech likely to attend pre-submission meeting with WHO for Covaxin emergency use listing | Latest News India - Hindustan Times
close_game
close_game

Bharat Biotech likely to attend pre-submission meeting with WHO for Covaxin emergency use listing

By | Written by Deepali Sharma | Edited by Amit Chaturvedi, Hindustan Times, New Delhi
Jun 23, 2021 09:35 AM IST

In a major boost to Bharat Biotech, the WHO on June 18 accepted its Expression of Interest (EoI) for Covaxin and scheduled a pre-submission meeting for Wednesday.

Bharat Biotech, manufacturer of India's homegrown vaccine against Covid-19 Covaxin, may attend a pre-submission meeting with World Health Organization on Wednesday, a step that will push the vaccine producer closer to WHO emergency use listing (EUL). As per the WHO, the vaccine manufacturer will have an opportunity to submit a summary on the overall quality of the shot.

Bharat Biotech said that it expects approval for its Covid vaccine from the health organisation for emergency use listing during July to September.(Sanchit Khanna / HT PHOTO)
Bharat Biotech said that it expects approval for its Covid vaccine from the health organisation for emergency use listing during July to September.(Sanchit Khanna / HT PHOTO)

In a major boost to the Hyderabad-based firm, the WHO on June 18 accepted its Expression of Interest (EoI) for Covaxin and scheduled a pre-submission meeting for Wednesday.

Hindustan Times - your fastest source for breaking news! Read now.

Also read: Covaxin submits Phase 3 data to expert panel, claims 78% efficacy

Last month, Bharat Biotech said that it expects approval for its Covid vaccine from the health organisation for emergency use listing during July to September.

EUL is the procedure to streamline the process by which new of unlicensed products can be used during public health emergencies like the coronavirus pandemic, according to the WHO.

The pre-submission meetings do not require the manufacturer to submit a detailed report about the jab but provide an opportunity for advice and guidance before the submission of a medicines dossier. It also offers an opportunity for the applicant to meet WHO medicine assessors who will be involved in assessing their product, as per the organization.

"The pre-submission meeting does not include a detailed review of data or full study reports. However, an essential aspect of the meeting is the submission (at least two weeks in advance of the pre-submission meeting) of a completed QOS-PD (Quality overall summary product dossiers)," WHO explained the process of the pre-scheduled meeting, PTI reported.

Bharat Biotech has conveyed to the Centre, as per previous reports, that it has already submitted 90 per cent of the documents to WHO for the getting EUL for Covaxin. The company said that it expects to submit the remaining documents by June.

Meanwhile, an expert panel of the country's central drugs authority reviewed and accepted the phase 3 trial data of Covaxin on Tuesday. "The required data was submitted by the company, and the subject expert committee went though it today. The experts were satisfied with the results presented, and the vaccine efficacy is confirmed at 77.8%," said an official in the government aware of the development, on condition of anonymity.

The firm had submitted the results of its phase-3 trial efficacy data of Covaxin to the Drugs Controller General of India (DCGI) over the weekend.

Unveiling Elections 2024: The Big Picture', a fresh segment in HT's talk show 'The Interview with Kumkum Chadha', where leaders across the political spectrum discuss the upcoming general elections. Watch now!

Get Current Updates on India News, Election 2024, Mukhtar Ansari Death News Live, Bihar Board 10th Result 2024 Live along with Latest News and Top Headlines from India and around the world.
SHARE THIS ARTICLE ON
Share this article
SHARE
Story Saved
Live Score
OPEN APP
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Friday, March 29, 2024
Start 14 Days Free Trial Subscribe Now
Follow Us On